Estimates made of the burden of fungal infections for 80% of the world
GAFFI and its partners have estimated the global burden of serious fungal infections for >6 billion people (over 80% of the world’s population) including Algeria, Argentina, Australia, Austria, Azerbaijan, Bangladesh, Belgium, Belarus, Benin, Bolivia, Brazil, Burkina Faso, Cameroon, Canada, Chile, China, Congo, Congo (Republic of), Costa Rica, Cote d’Ivoire, Cuba, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Ethiopia, France, Germany, Ghana, Greece, Guatemala, Honduras, Hungary, India (3 topics), Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kyrgyzstan, Madagascar, Malawi, Malaysia, Mexico, Mongolia, Mozambique, Namibia, Nepal, Netherlands, New Zealand, Nicaragua, Nigeria, Norway, Qatar, Pakistan, Panama, Paraguay, Peru, Philippines, Portugal, Romania, Russia, Saudi Arabia, Senegal, Serbia, Singapore, South Africa, South Korea, Spain, Sri Lanka, Sudan, Sweden, Taiwan, Tanzania, Thailand, Tijakistan, Trinidad and Tobago, Togo, Turkey, Uganda, UK, Ukraine, Uruguay, Uzbekistan, Venezuela, Vietnam and Zambia: https://www.gaffi.org/media/academic-papers/
Successfully lobbied the WHO to place itraconazole, voriconazole and natamycin 5% ophthalmic solution onto the Essential Medicines List (EML) to treat aspergillosis, histoplasmosis, sporotrichosis, chromoblastomycosis T. marneffei infection and other skin infection, as well as fungal keratitis, in a coalition with the Instituto de Salud Carlos III, International Foundation for Dermatology, London School of Hygiene of Tropical Medicine and The University of Manchester. https://www.gaffi.org/ruling-by-world-health-organisation-delights-doctors/
Successfully lobbied the WHO to place amphotericin B and flucytosine on the Essential Medicines List to treat cryptococcal meningitis and other life-threatening fungal infections, in a coalition with other agencies including US Centres for Disease Control, attendees from LIFE, WHO, Medicines Sans Frontieres (MSF), Clinton Health Access and numerous universities and public health institutions.” View selection and use of Essential Medicines.
Launched the 10 year Roadmap ‘95-95 by 2025’ at ISHAM conference in Melbourne, calling on all national governments and public health agencies to reduce the toll of death and blindness from fungal diseases. 95-95 means 95% of patients with life or sight-threatening fungal disease will be diagnosed and 95% treated by 2025. GAFFI proposed a target of reducing AIDS deaths to under 500,000 by 2020, which has been adopted by UNAIDS as a key target. 10 year ’95-95 by 2025′ GAFFI Roadmap.
Successfully applied for the WHO to recommend to the World Health Assembly for the disfiguring skin disease chromoblastomycosis to be included as a Neglected Tropical Disease (NTD), with support form the governments of Brazil and Madagascar. View press release.
GAFFI has pointed out in a perspective published in the CDC journal Emerging Infectious Diseases that availability of rapid, non-culture based diagnostics for fungal diseases are essential in the fight against Antimicrobial Resistance (AMR) by limiting unnecessary anti-bacterial therapy. View press release.
GAFFI has modelled how many lives could be saved from AIDS over 5 years with 60% implementation of fungal diagnostics and antifungal drug availability for cryptococcal meningitis, disseminated histoplasmosis, Pneumocystis pneumonia (PCP) and chronic pulmonary aspergillosis – over 1 million. View press release.
GAFFI drafted the revisions to the International Classification of Diseases for ICD11, in collaboration with the WHO. https://icd.who.int/en This is crucial to the collection of data internationally, as data is coded using ICD codes all over the world.
Supported the cryptococcal disease access programme (CryptoMAG), a collaboration between the WHO (HIV Treatment and Care), CDC (Mycotic Diseases Branch), MSF (Access Campaign), Clinton Health Access Initiative and Management Sciences for Health (Technical Strategy and Quality Center for Pharmaceutical Management).
Supports the Histoplasmosis Action Group (HistoAG) a collaboration between numerous clinicians and researchers, the US Centers for Disease Control, Caribbean Public Health Agency and Prevention and the Pan-American Health Organisation which issued the Manaus Declaration in March 2019 calling for “ Every American country to have access to rapid testing for histoplasmosis (antigen or PCR/molecular) and availability of itraconazole and both standard and lipid formulations of amphotericin B.” View